TransThera Sciences Nanjing, Inc. (the "TransThera") announced that the new drug application for Tinengotinib tablets has been accepted by the Center for Drug Evaluation ("CDE")of the National Medical ...
TipRanks on MSN
TransThera’s tinengotinib NDA for advanced cholangiocarcinoma accepted by China’s drug regulator
TransThera Sciences (Nanjing). Inc. ( (HK:2617) ) has provided an announcement.
NANJING, China and GAITHERSBURG, Md., Dec. 18, 2025 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced that the new drug application for ...
Tinengotinib shows activity in FGFR-altered cholangiocarcinoma post-FGFR inhibitor therapy. Learn more about the phase 2 ...
Genfit has announced encouraging preliminary results from its phase 1b clinical trial evaluating investigational drug GNS561 in combination with a MEK inhibitor (MEKi) in patients with KRAS mutated ...
The latest update is out from TransThera Sciences (Nanjing). Inc. ( (HK:2617) ).
TransThera Sciences Inc. ("TransThera") announced the publication of clinical results from a US-based Phase 2 trial evaluating tinengotinib in patients with Cholangiocarcinoma (CCA) on The Lancet ...
The test, a cell-free DNA test, uses a sample of the mother's blood to screen for certain conditions in the developing fetus ...
The new treatment offers a median overall survival of 29.3 months for eligible AML patients and 10.3 months for those with intrahepatic cholangiocarcinoma, according to clinical data cited by the comp ...
Sydney Towle, 26, has recently been documenting her treatments in a clinical trial for her rare, aggressive bile duct cancer.
Highly encouraging early data from the ongoing Phase 1b study evaluating investigational drug GNS561 with a MEK inhibitor (MEKi) in KRAS mutated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback